Next-generation exosome solutions developer INOVIQ Limited (ASX:IIQ) and ResearchDx Inc have signed a license and supply agreement covering INOVIQ’s EXO-NET exosome capture technology.
The ResearchDx partnership builds on the previously announced Joint Marketing Agreement for INOVIQ’s EXO-NET exosome capture technology and Promega Nucleic Acid purification systems
INOVIQ and ResearchDx have signed a license and supply agreement that will enable the companies to deliver EXO-NET enabled High-Throughput (HT) exosome isolation, biomarker discovery and diagnostics development services to customers in the USA. Establishment of EXO-NET services in the USA follows the recent introduction of INOVIQ’s EXO-NET services from its Australian laboratory.
This new agreement combines the expertise of ResearchDx in the development and validation of IVD diagnostics, with INOVIQ’s disruptive EXO-NET technology, exosome capture tools and exosome- based diagnostics expertise.
Under the agreement, US customers will be offered a wide range of contract research services from ResearchDx using INOVIQ’s EXO-NET exosome capture tools to suit their exosome isolation, biomarker discovery and diagnostics development needs.
INOVIQ and ResearchDx are excited to leverage their combined exosome and IVD diagnostics development expertise to advance exosome-based diagnostics development for companion diagnostics to deliver the right medicines to the right patients to improve therapeutic outcomes.
ResearchDx is a key part of our strategy to expand INOVIQ’s EXO-NET exosome services in the USA. It builds on our established and successful contract research relationship with them for development of our SubB2M tests,” INOVIQ CEO, Dr Leearne Hinch, said.
“By partnering with ResearchDx, US customers now have access to a full range of EV isolation, biomarker discovery and diagnostic development services by a CAP and CLIA accredited Contract Research Organisation.
“This is an important, strategic move that enables us to provide high quality EXO-NET services to customers in
the US, Australia and elsewhere, expanding our revenue generation opportunities for EXO-NET.”